T. Rowe Price Associates
ABVX

T. Rowe Price Associates’s Abivax ABVX Stock Holding History

T. Rowe Price Associates’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77M Buy
691,670
+40,026
+6% +$4.74M 0.01% 665
2025
Q4 		$87.9M Buy
651,644
+171,775
+36% +$18.7M 0.01% 663
2025
Q3 		$40.7M Buy
+479,869
New +$29.4M ﹤0.01% 865

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

T. Rowe Price Associates's ABVX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Abivax (ABVX) stake by 6.1% in Q1 2026, buying an estimated $4.74M and bringing the position to 691,670 shares worth $77M. The position accounts for 0.01% of the portfolio, ranked #665.

T. Rowe Price Associates first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $87.9M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • T. Rowe Price Associates held 691,670 shares of Abivax worth $77M as of Q1 2026.
  • T. Rowe Price Associates bought 40,026 Abivax shares in Q1 2026, an estimated $4.74M.
  • Abivax made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #665 holding.
  • T. Rowe Price Associates first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • T. Rowe Price Associates's Abivax position peaked at $87.9M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.